Sure. I'm happy to jump in. Thank you for the question.
Of course, it was for a number of reasons that we witnessed over the last 30 to 40 years a decline in manufacturing capacity in Canada. Essentially, from the early 1970s we went from importing about 20% of our vaccines and therapeutic drugs to over 85% today. We saw a number of factors over the course of these years. One was companies concentrating their manufacturing in large markets where there are cost advantages and other underlying factors.
I think the key thing you're raising here is to make sure that we have an ecosystem that's supported, from discovery to clinical trials to commercialization and end-stage production. By focusing the strategy on all of the value chain, making those investments across the value chain and ensuring that we're developing flexible manufacturing capacity, in non-pandemic times, when those facilities are not focused on a specific vaccine, they can be put to other uses. For example—